Gothenburg, Sweden, 23.04. 2009.
Denator AB announced today an agreement with Harvard Catalyst - Laboratory for Innovative Translational Technologies (HC-LITT) at Harvard Catalyst | The Harvard Clinical and Translational Science Center that will give the Harvard research community access to the company's StabilizorTM system for stabilizing biological samples.
HC-LITT was established to enable researchers to bridge the "innovation gap" between academia and industry. A central component of Harvard Catalyst, a primary goal of HC-LITT is to provide the Harvard research community with early access to new, enabling, leading-edge technologies, LITT hope to accelerate the translation of laboratory research in therapeutics and diagnostics into the clinic.
HC-LITT Director Winston Patrick Kuo DMSc, DDS, says: "Denator's rapid heat inactivation technology, Stabilizor T1, which stabilizes tissues instantly and ensures that this stability is maintained during downstream analyses, nicely complements the set of downstream technologies currently used at HC-LITT and local proteomic core facilities. We are very pleased to include the instrument in our suite of enabling leading-edge genomic and proteomic technologies. This new approach is expected to have a large impact on sample preparation and handling in the future."
Olof Sköld, CEO at Denator, stated: "We are extremely pleased that Dr. Kuo's laboratory has taken the decision to include our technology in HC-LITT's instrument park. To get exposure to key research laboratories and researchers within the Harvard community and to obtain user feedback on the performance of our technology is highly valuable for us. The model utilized at HC-LITT, where leading-edge technologies are put to use in the hands of investigators from diverse disciplines with the goal of addressing questions with human translational impact, will ultimately facilitate the acceptance of the Stabilizor technology."
Denator's first commercial system for tissue stabilization was launched at the HUPO meeting in Amsterdam in August, 2008.
About Harvard Catalyst | The Harvard Clinical and Translational Science Center
Harvard Catalyst | The Harvard Clinical and Translational Science Center brings together the intellectual force, technologies, and clinical expertise at Harvard University and its academic, health care, and community partners to create connections, enable research at the cutting edge of discovery, and nurture clinical and translational researchers with the goal of improving human health. Harvard Catalyst is supported by a Clinical and Translational Science Award from the National Center for Research Resources, a component of the National Institutes of Health, as well as commitments from its partner organizations. The resources of Harvard Catalyst are available to all faculties at Harvard University, regardless of institutional affiliation or academic degree. For more information on Harvard Catalyst, visit http://catalyst.harvard.edu.
Denator intends to become the leading supplier of products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company's proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation immediately and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com or contact:
Charlotte Emlind Vahul
Tel.: +46 31 41 28 91
Fax.: +46 31 41 28 40
Stabilizor is a trademark of Denator AB.